Immunogenicity and Safety of a Recombinant Tetravalent Dengue Vaccine in Children and Adolescents Ages 9–16 Years in Brazil

Immunogenicity and safety of a recombinant, live-attenuated, tetravalent dengue disease vaccine (CYD-TDV) was evaluated in children/adolescents in Brazil. In this observer-blind, placebo-controlled, phase II single-center study, children/adolescents (ages 9–16 years) were randomized to receive CYD-T...

Descripción completa

Detalles Bibliográficos
Autores principales: Dayan, Gustavo H., Garbes, Pedro, Noriega, Fernando, de Sadovsky, Ana Daniela Izoton, Rodrigues, Patricia Marques, Giuberti, Camila, Dietze, Reynaldo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Tropical Medicine and Hygiene 2013
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854882/
https://www.ncbi.nlm.nih.gov/pubmed/24189367
http://dx.doi.org/10.4269/ajtmh.13-0304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854882/
https://www.ncbi.nlm.nih.gov/pubmed/24189367
http://dx.doi.org/10.4269/ajtmh.13-0304

Ejemplares similares